NEWPORT BEACH, California | January 9, 2026 — Evolus, Inc., a global performance beauty company specializing in aesthetic injectable products, has announced preliminary unaudited net revenue results for the fourth quarter and full year 2025, alongside forward-looking guidance for 2026 and an updated long-term financial outlook through 2028. The results highlight double-digit annual growth, positive non-GAAP operating income in Q4 2025, and a clear trajectory toward sustainable annual profitability beginning in 2026, underscoring the company’s continued momentum in the competitive aesthetics market.
Science Significance
From a scientific and product innovation standpoint, Evolus’ performance reflects increasing adoption of its injectable aesthetics portfolio, including Jeuveau®, a neurotoxin dedicated exclusively to aesthetic use, and Evolysse™ injectable hyaluronic acid (HA) gels. These products are designed to meet evolving consumer expectations for predictable outcomes, aesthetic precision, and treatment consistency. The growing contribution of HA gels to total revenue signals expanding clinician confidence in next-generation dermal filler technologies, which rely on advanced formulation science to optimize tissue integration, durability, and aesthetic results. Continued portfolio expansion demonstrates how scientific formulation advances directly support commercial scalability in the aesthetics sector.
Regulatory Significance
Regulatory considerations remain central to Evolus’ growth strategy. The company’s guidance reflects ongoing regulatory approvals and anticipated filings across multiple geographies, including the U.S. commercialization of Evolysse™ Form and Evolysse™ Smooth and the expected European launch of Estyme®. Importantly, no revenue contribution is assumed from Evolysse™ Sculpt in 2026, pending anticipated regulatory approval in late 2026, highlighting a disciplined, compliance-aligned forecasting approach. This demonstrates adherence to global regulatory frameworks governing injectable aesthetics, reinforcing the importance of quality systems, post-market surveillance, and regulatory readiness in sustaining long-term growth.
Business Significance
Advertisement
From a business perspective, Evolus reported preliminary unaudited Q4 2025 net revenue of $88.6 million to $90.6 million, representing 12% to 15% year-over-year growth, and full-year 2025 revenue of $295.5 million to $297.5 million, reflecting 11% to 12% annual growth. The company reaffirmed positive non-GAAP operating income of $5 million to $7 million for Q4 2025, a key milestone demonstrating operational leverage. Looking ahead, 2026 net revenue guidance of $327 million to $337 million and an updated 2028 outlook of $450 million to $500 million in total revenue position Evolus for durable, profitable expansion, supported by international growth and disciplined cost management.
Patients’ Significance
For patients and consumers, Evolus’ continued growth translates into broader access to regulated, high-quality aesthetic injectable treatments delivered through trained healthcare professionals. Expanding product availability across regions supports consistent treatment standards and safety expectations, while portfolio diversification allows practitioners to tailor treatments to individual aesthetic goals and anatomical needs. As the aesthetic market matures, reliable supply, regulatory oversight, and ongoing product innovation contribute to patient confidence, predictable outcomes, and improved overall treatment experiences.
Policy Significance
At a policy level, Evolus’ performance underscores the growing importance of regulatory oversight, product transparency, and quality compliance in the global aesthetics industry. As injectable cosmetic procedures continue to rise, regulators and policymakers increasingly emphasize patient safety, manufacturing quality, and truthful performance claims. Evolus’ conservative revenue assumptions tied to regulatory approvals and its focus on sustainable profitability align with policy objectives aimed at responsible industry growth without compromising public health protections.
In summary, Evolus’ preliminary 2025 financial results and forward-looking guidance highlight a company executing at the intersection of science-driven product innovation, regulatory discipline, and commercial scale. With expanding global reach, a growing injectable portfolio, and a clear path toward sustained profitability, Evolus is reinforcing its position as a leading performance beauty company. As regulatory approvals progress and market conditions normalize, the company’s strategy positions it to deliver long-term value for stakeholders while maintaining high standards of quality and compliance.
Source: Evolus press release
